Amiodarone Treatment Investigation on the Correlation between the Drug Sensitivity for Paroxysmal Atrial Fibrillation and Gene Polymorphism

Objective: To investigate the correlation between the sensitivity to amiodarone therapy and the polymorphism of KCNN3 gene rs13376333 site and ZFHX3 gene rs7193343 site in patients with paroxysmal atrial fibrillation (AF). Materials and Methods: A total of 100 patients comprised 57 men and 43 women with paroxysmal AF hospitalized in Xinhua Hospital were selected between November 1, 2014, and April 30, 2016. Their clinical data and peripheral venous blood samples were collected for case–control study. Patients with recovered to sinus rhythm that was maintained for 6 months in response to amiodarone treatment were included in the observational group. Patients whose rhythm could not be converted to sinus rhythm after amiodarone treatment or who had recurrence within 6 months were included in the control group. DNA of the white blood cells collected from the peripheral venous blood was extracted for each group. The polymerase chain reaction-restriction fragment length polymorphism method and gene sequencing were used to detect the genotype of KCNN3 gene rs13376333 site and ZFHX3 gene rs7193343 site in all the patients. The polymorphism in KCNN3 gene rs13376333 site and ZFHX3 gene rs7193343 was analyzed between the observational and control groups. Results: Three genotypes for KCNN3 gene rs13376333 in the observational and control groups were identified: TT, TC, and CC. The genotype frequency was 26% versus 20% for TT, 40% versus 36% for TC, and 34% versus 44% for CC and 46% versus 38% for T allele and 54% versus 62% for C allele, respectively. However, differences were not statistically significant (P > 0.05). More patients in the observational group carried T allele than that in the control group. Logistic regression indicated a 1.21-fold increase in sensitivity to amiodarone by T allele for the treatment of paroxysmal AF (odds ratio [OR] =1.21, P > 0.05). However, this result was not statistically significant. There were three genotypes for ZFHX3 gene rs7193343 site in both groups: 28% versus 42% for TT, 42% versus 42% for TC and 30% versus 16% for CC and 49% versus 63% for T allele and 51% versus 37% for C allele, respectively. More patients in the observational group carried C allele than that in the control group. Logistic regression indicated a 1.32-fold increase in the sensitivity to amiodarone by the C allele for the treatment of paroxysmal AF (OR = 1.32, P < 0.05). Conclusion: Gene polymorphism was present at KCNN3 gene rs13376333 site and ZFHX3 gene